Novo Nordisk Foundation Unveils Strategic Roadmap to Revitalize Regenerative Medicine in Europe
Key Insights
The Novo Nordisk Foundation (search) released a comprehensive report outlining a strategic roadmap to position Europe as a global leader in regenerative medicine, developed in collaboration with Catenion (search).
Only a handful of regenerative medicine therapies have gained approval in the past two decades, with critical gaps identified in translation, private investment, and ecosystem coordination.
The report identifies four strategic priorities: concentrating efforts in high-potential hubs, embedding commercial thinking early, improving shared infrastructure, and applying rigorous project prioritization.
The Novo Nordisk Foundation (search) has released a comprehensive report detailing a strategic roadmap aimed at transforming Europe into a world-leading hub for regenerative medicine. Published following an in-depth analysis of the European regenerative medicine landscape conducted by Catenion (search), the report calls for a decisive shift from fragmented efforts toward coordinated, system-level action to translate scientific breakthroughs into patient therapies.
Despite the field's phenomenal potential to reverse or halt disease progression, only a handful of regenerative medicine therapies have gained approval over the past two decades. The report identifies critical gaps that must be addressed, including insufficient well-funded companies and declining private capital investment.
"Regenerative medicine has phenomenal potential to treat, or even cure, disease. But so few therapies make it to patients, often getting stuck in development despite strong underlying science," said Tanja Xenia Pedersen, Vice President, Biomedical Research at the Novo Nordisk Foundation (search). "This analysis gives us a clearer picture of what's holding the field back – and what it will take to move it forward."
Persistent Barriers Across the Value Chain
The report highlights that no single barrier prevents therapies from reaching patients; rather, a combination of challenges spans the entire value chain. Europe produces excellent science, but moving ideas from academia or early-stage companies into clinical development remains exceedingly difficult.
Funding represents a major obstacle, particularly in attracting private investment. "Investors understandably need a clear business case and that isn't always built in early enough," Pedersen explained. The inherent complexity of regenerative medicine compounds the challenge, as working with living cells makes characterization, manufacturing, and consistent scale-up difficult, driving high costs and complicating industrialization.
Regulatory and access barriers further slow progress. Developers often face unclear or evolving approval pathways, and even when therapies reach the market, reimbursement models remain poorly established. More broadly, the ecosystem is fragmented, lacking coordination from discovery through manufacturing to clinical development, which reduces investor confidence.
Europe's Global Standing
The report draws on a multi-parametric analysis of 350 European bioclusters alongside successful regenerative medicine bioclusters in Japan, China, Singapore, Canada, and the United States. Across indicators such as company formation, clinical trial activity, and investment, regions like the United States and increasingly parts of Asia are moving faster.
Even Europe's most successful regenerative medicine bioclusters — including London, Paris, Cambridge, Medicon Valley, and Munich — have not been as effective at converting scientific excellence into commercial and clinical progress. Differences in funding environments and risk appetite play a significant role, with venture capital generally more available and willing to take risks in the US and parts of Asia.
Four Strategic Priorities
The roadmap outlines four priority areas to strengthen Europe's regenerative medicine ecosystem:
First, concentrating efforts in existing high-potential hubs to achieve critical mass, integrating high-quality science with drug development thinking, entrepreneurship, and intellectual property strategy. "Europe already has strong regenerative medicine activity in several places, but no single cluster yet has the depth needed to deliver repeated clinical and commercial successes," Pedersen noted.
Second, embedding strategic and commercial thinking from the outset to attract investors. This means asking critical questions about unmet need, manufacturability, reimbursement, and business case early in the research process. Public or philanthropic funding can help de-risk programs, strengthening the case for private investors later.
Third, improving manufacturing efficiency and developing shared infrastructure to avoid every company or academic spinout having to build capabilities from scratch. The report describes a "one-stop shop" concept where project developers could access coordinated guidance on process optimization, GMP scale-up, regulatory consultations, and business development.
Fourth, applying rigorous strategic prioritization across initiatives, using disease mapping and pipeline evaluation panels to identify therapeutic areas with significant unmet needs and attractive business cases.
Translating Strategy into Action
The Novo Nordisk Foundation (search) has already begun implementing elements of this vision through initiatives including the Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Cellerator (search) — which focuses on manufacturing and clinical readiness — and Regenerative Medicine Catalyst Grants designed to overcome specific translational hurdles.
A recent success illustrates the approach: with support from Cellerator (search) and the BioInnovation Institute (search), reNEW spun out its first company, Ibnova Therapeutics (search), which is developing stem-cell-based heart patches to treat heart failure (search).
"At the Novo Nordisk Foundation (search), we are working to help fill critical gaps — in fundamental research, translation, manufacturing, and early clinical development, in close collaboration with partners," Pedersen said. "Now, the priority is to act on this roadmap together, so more scientific breakthroughs can ultimately benefit patients."
Looking ahead, successful implementation could yield tangible shifts within five to ten years: a stronger, more coordinated European ecosystem, more programs progressing into clinical development, and systemic barriers beginning to ease through better coordination across hubs and clearer regulatory pathways. Ultimately, the goal is to close the gap between scientific promise and real patient benefit, enabling more people living with serious or chronic conditions to access potentially curative treatments.